Ollin’s next-gen VEGF/Ang2 antibody shows superiority over faricimab in Phase 1b trial
Ollin’s OLN324 outperformed faricimab in a head-to-head retinal trial. Find out how this could change first-line treatment in DME and wAMD.
Innovent–Ollin’s bispecific antibody OLN324 delivers superior retinal drying in DME
Ollin Biosciences and Innovent Biologics have reported positive topline results from the randomized Phase 1b JADE trial, in which OLN324 (IBI324), a next-generation VEGF/Ang2 bispecific antibody, demonstrated superior anatomical efficacy over faricimab in patients with diabetic macular edema and wet age-related macular degeneration. Conducted in over 160 patients across the United States, the head-to-head study […]
Outlook’s bevacizumab for wet AMD rejected again: What’s holding back FDA approval?
FDA rejects Outlook Therapeutics’ ONS-5010 for wet AMD again. Find out what this means for U.S. approval and how European expansion could reshape strategy.